Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial

The Lancet

Volumn 371, Issue 9631, 2008, Pages 2192-2200

  Schottenfeld, Richard S ^a   Chawarski, Marek C ^a   Mazlan, Mahmud ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Substance Abuse Center   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; CLONIDINE; DIAZEPAM; METOCLOPRAMIDE; NALTREXONE; NAPROXEN; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DETOXIFICATION; DRUG EFFICACY; DRUG USE; DRUG WITHDRAWAL; HEROIN DEPENDENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALAYSIA; PATIENT COUNSELING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RISK FACTOR; SEXUAL BEHAVIOR; TREATMENT OUTCOME; URINALYSIS; WITHDRAWAL SYNDROME;

EID: 45849084312     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60954-X     Document Type: Article

References (42)

1. Aceijas C., Stimson G., Hickman M., Rhodes T., and United Nations Reference Group on HIV/AIDS Prevention and Care among IDU in Developing and Transitional Countries. Global overview of injecting drug use and HIV infection among injecting drug users. AIDS 18 (2004) 2295-2303
2. UNAIDS (Joint UN Programme on HIV/AIDS). UNAIDS 2006 report on the global AIDS epidemic: a UNAIDS 10th anniversary special edition (2006), UNAIDS, Geneva
3. Institute of Medicine Committee on the Prevention of HIV Infection among Injecting Drug Users in High Risk Countries. Preventing HIV infection among injecting drug users in high risk countries (2006), The National Academies Press, Washington, DC
4. Chawarski M., Schottenfeld R., and Mazlan M. Heroin dependence and HIV infection in Malaysia. Drug Alcohol Depend 82 suppl 1 (2006) S39-S42
5. Sullivan L., Metzger D., Fudala P., and Fiellin D. Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users. Addiction 100 (2005) 150-158
6. International Narcotics Control Board. Part four: Statistical information on narcotic drugs. Narcotic Drugs: estimated world requirements for 2006: statistics for 2004 (2005), United Nations, New York
7. Mazlan M., Schottenfeld R., and Chawarski M. New challenges and opportunities in managing substance abuse in Malaysia. Drug Alcohol Rev 25 (2006) 473-478
8. Krupitsky E., Zvartau E., Masalov D., et al. Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. J Subst Abuse Treat 31 (2006) 319-328
9. Substance Abuse and Mental Health Services Administration-Office of Applied Studies. National Survey of Substance Abuse Treatment Servicies (N-SSATS): 2004 data on substance abuse treatment facilities. Publication number (SMA) 05-4112 (2005), DHHS, Rockville, MD
10. Mayet S., Farrell M., Ferri M., Amato L., and Davoli M. Psychosocial treatment for opiate abuse and dependence. Cochrane Database Syst Rev 3 (2006) CD004330.
11. Minozzi S., Amato L., Vecchi S., Davoli M., Kirchmayer U., and Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 1 (2006) CD001333.
12. Johansson B., Berglund M., and Lindgren A. Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review. Addiction 101 (2006) 491-503
13. Krupitsky E., Zvartau E., Masalov D., et al. Naltrexone for heroin dependence treatment in St. Petersburg, Russia. J Subst Abuse Treat 26 (2004) 285-294
14. Mattick R., Breen C., Kimber J., and Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2 (2003) CD002209.
15. Mattick R., Kimber J., Breen C., and Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2 (2003) CD002207.
16. Gowing L., Ali R., and White J. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev 4 (2004) CD002025.
17. Johnson R., Chutuape M., Strain E., Walsh S., Stitzer M., and Bigelow G. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 343 (2000) 1290-1297
18. Fudala P., Bridge T., Herbert S., et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 349 (2003) 949-958
19. Fiellin D., Pantalon M., Chawarski M., et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med 355 (2006) 365-374
20. Ling W., Charuvastra C., Collins J., et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. Addiction 93 (1998) 475-486
21. Kakko J., Svanborg K., Kreek M., and Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 361 (2003) 662-668
22. Krook A., Brors O., Dahlberg J., et al. A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway. Addiction 97 (2002) 533-542
23. Johnson R., Eissenberg T., Stitzer M., Strain E., Liebson I., and Bigelow G. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend 40 (1995) 17-25
24. San L., Pomarol G., Peri J., Olle J., and Cami J. Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts. Br J Addict 86 (1991) 983-990
25. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV-TR) (2000), American Psychiatric Publishing, Washington, DC
26. O'Connor P., Waugh M., Weiss E., et al. A comparison of clonidine, clonidine/naltrexone, and buprenorphine in primary care-based ambulatory opioid detoxification. Clin Res 41 (1993) 545A
27. Chawarski M., Schottenfeld R., Pakes J., and Avants K. AIDS Risk Inventory (ARI): a structured interview for assessing risk of HIV infection in a population of drug abusers. In: Harris L. (Ed). Problems of drug dependence, 1996: proceedings of the 58th Annual Scientific Meeting of the College on Problems of Drug Dependence, NIDA Research Monograph number 174 (1997), National Institute on Drug Abuse, Rockville
28. Schottenfeld R., Pakes J., Oliveto A., Zeidonis D., and Kosten T. Buprenorphine versus methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry 54 (1997) 713-720
29. Lawless J. Statistical models and methods for lifetime data. 2nd edn. (2003), John Wiley and Sons, Hoboken
30. Miotto K., McCann M., Rawson R., Frosch D., and Ling W. Overdose, suicide attempts and death among a cohort of naltrexone-treated opioid addicts. Drug Alcohol Depend 45 (1997) 131-134
31. Sullivan M., and Nunes E. New-onset mania and psychosis following heroin detoxification and naltrexone maintenance. Am J Addict 14 (2005) 486-487
32. Kakko J., Gronbladh L., Svanborg K., et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry 164 (2007) 797-803
33. National Research Council Committee on Clinical Evaluation of Narcotic Antagonists. Clincial evaluation of naltrexone treatment of opaiate-dependent individuals. Arch Gen Psychiatry 35 (1978) 335-340
34. Curran S., and Savage C. Patient response to naltrexone: issues of acceptance, treatment effects, and frequency of administration. NIDA Res Monogr 9 (1976) 67-69
35. Fals-Stewart W., and O'Farrell T. Behavioral family counseling and naltrexone for male opioid-dependent patients. J Consult Clin Psychol 71 (2003) 432-442
36. Carroll K., Ball S., Nich C., et al. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement. Arch Gen Psychiatry 58 (2001) 755-761
37. Cornish J., Metzger D., Woody G., et al. Naltrexone pharmacotherapy for opioid dependent federal probationers. J Subst Abuse Treat 14 (1997) 529-534
38. Comer S., Sullivan M., Yu E., et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 63 (2006) 210-218
39. Gowing L., Farrell M., Bornemann R., and Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev 4 (2004) CD004145.
40. Montori V., Devereaux P., Adhikari N., et al. Randomized trials stopped early for benefit: a systematic review. JAMA 294 (2005) 2203-2209
41. Pocock S. When (not) to stop a clinical trial for benefit. JAMA 294 (2005) 2228-2230
42. Lofwall M., Stitzer M., Bigelow G., and Strain E. Comparative safety and side effect profiles of buprenorphine and methadone in the outpatient treatment of opioid dependence. Addict Disord Treat 4 (2005) 49-64